中国药物警戒 ›› 2016, Vol. 13 ›› Issue (11): 697-700.

• 安全性评价与合理用药 • 上一篇    下一篇

加强重点药品监测提高药品不良反应上报率的实践

王华，李忻，于倩*   

  1. 吉林大学中日联谊医院药学部,吉林 长春 130033
  • 收稿日期:2016-12-05 修回日期:2016-12-05 出版日期:2016-11-20 发布日期:2016-12-05
  • 作者简介:王华,女,博士,主任药师,临床药学。

Strengthening Key Drug Monitoring to Enhance the Adverse Drug Reactions Reporting Rate

WANG Hua, LI Xin ,YU Qian*   

  1. Department of Pharmacy, China-Japan Union Hospital of Jilin University, Jilin Changchun 130031, China
  • Received:2016-12-05 Revised:2016-12-05 Online:2016-11-20 Published:2016-12-05
  • Contact: 于倩,女,博士,主任药师,临床药学。E-mail：819389186@qq.com

PDF (PC)

169

摘要： 目的 监测临床实际发生的药品不良反应,提高不良反应上报率。方法 确定发生不良反应时使用的急救药物和抗过敏药物等相关特定药品,抽取临床使用特定药品的病例,分析辨别其使用目的 ,筛查出漏报的不良反应。结果 通过对特定药品使用情况的筛查和监测,我院2015年6—12月药品不良反应上报数量占筛查出数量的比例为91.16%,明显高于2014年临床自觉上报的比例25.47%,以及2015年1—5月临床自觉上报的比例30.24%。结论 采用重点监测几种特定药品使用的方法 ,能够有效提高药品不良反应的上报率,该方法简单高效,值得在医院推广使用。

关键词: 急救药物, 抗过敏药物, ADR, 报告与监测

Abstract: Objective To enhance the reporting rate of adverse drug reactions through monitoring the actual occurrence of clinical drug adverse reactions. Methods We determined the related specific drugs like first-aid medicines and antiallergic drugs when the adverse reactions occurred. In addition, we extracted the clinical use of drugs specific cases to identify the purpose of usage and screened underreporting of adverse reactions. Results Through the specific drug use screening and monitoring of our hospital from June to December in 2015, the number of reported adverse drug reactions accounted for 91.16% of screening out number, significantly higher than clinical subjective reporting proportion (25.47%) in 2014, and clinical subjective reporting proportion (30.24%) from January to May 2015. Conclusion The method of intensively monitoring the usage of several specific drugs is simple and efficient, which can effectively enhance the reporting rate of adverse drug reactions. Therefore, it is worth to promote in hospital.

Key words: first-aid medicine, antiallergic drug, ADR, reporting and monitoring.

中图分类号: